Bank Norwegian AS
Bank Norwegian AS refers to the announcement on 8 March 2021. The bank has today issued two senior preferred bonds denominated in NOK and SEK with the following terms:
NOK 700 million with a 4 year tenor with a call option for the issuer after 3 years and quarterly thereafter, with a coupon equal to 3 months NIBOR + 1.45% p.a.
SEK 300 million with a 4 year tenor with a call option for the issuer after 3 years and quarterly thereafter, with a coupon equal to 3 months STIBOR + 1.40% p.a.
The settlement date for both issues is 18 March 2021. The bonds are issued under Bank Norwegian’s EMTN programme, and will be applied for listing on Oslo Stock Exchange.
SpareBank 1 Markets and Swedbank acted as joint lead managers.
Contact persons:
CFO Klara-Lise Aasen; phone +47 47 63 55 83; kaa@banknorwegian.no
Head of treasury Mats Benserud; phone +47 95 89 15 39; mbe@banknorwegian.no
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
DBV Technologies S.A.17.1.2026 00:11:29 CET | Press release
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
Scandinavian Investment Group A/S16.1.2026 22:01:00 CET | Pressemeddelelse
Storaktionærmeddelelse
Scandinavian Investment Group A/S16.1.2026 22:00:00 CET | Pressemeddelelse
Ledende medarbejders transaktion
Tiziana Life Sciences Ltd.16.1.2026 20:45:30 CET | Press release
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
Genmab A/S16.1.2026 19:30:00 CET | Press release
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
